GoodRx (NASDAQ:GDRX) Shares Down 13.9% - Here's What Happened

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report)'s share price was down 13.9% on Thursday . The stock traded as low as $4.66 and last traded at $5.26. Approximately 1,170,042 shares traded hands during trading, a decline of 14% from the average daily volume of 1,366,152 shares. The stock had previously closed at $6.11.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Royal Bank of Canada reiterated an "outperform" rating and issued a $10.00 target price on shares of GoodRx in a research note on Friday, August 16th. Citigroup cut their target price on GoodRx from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Friday, August 9th. Raymond James raised GoodRx from an "outperform" rating to a "strong-buy" rating and set a $10.00 price objective on the stock in a research note on Friday, August 9th. Finally, UBS Group reduced their price target on shares of GoodRx from $9.00 to $8.50 and set a "neutral" rating for the company in a report on Friday, August 9th. One analyst has rated the stock with a sell rating, four have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, GoodRx currently has a consensus rating of "Moderate Buy" and an average price target of $9.36.

GoodRx Price Performance

The stock has a market cap of $1.89 billion, a price-to-earnings ratio of -38.85, a price-to-earnings-growth ratio of 3.71 and a beta of 1.39. The company has a debt-to-equity ratio of 0.96, a quick ratio of 7.32 and a current ratio of 7.32. The company has a 50-day simple moving average of $7.05 and a two-hundred day simple moving average of $7.54.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.08 EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.01). The firm had revenue of $200.60 million during the quarter, compared to the consensus estimate of $200.47 million. GoodRx had a negative net margin of 7.57% and a positive return on equity of 3.63%. The business's revenue was up 5.7% on a year-over-year basis. During the same period last year, the business earned $0.02 EPS. As a group, equities research analysts forecast that GoodRx Holdings, Inc. will post 0.14 EPS for the current year.

Insider Activity

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total value of $83,921.22. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 4.17% of the company's stock.

Institutional Investors Weigh In On GoodRx

Institutional investors have recently made changes to their positions in the company. Beacon Capital Management LLC bought a new stake in GoodRx in the 1st quarter valued at $28,000. nVerses Capital LLC bought a new position in GoodRx during the third quarter worth about $33,000. Plato Investment Management Ltd acquired a new stake in GoodRx in the 2nd quarter worth about $43,000. Dark Forest Capital Management LP bought a new stake in GoodRx in the 2nd quarter valued at about $86,000. Finally, EntryPoint Capital LLC increased its holdings in shares of GoodRx by 165.2% during the first quarter. EntryPoint Capital LLC now owns 18,538 shares of the company's stock worth $132,000 after purchasing an additional 11,548 shares during the period. Institutional investors own 63.77% of the company's stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.